- Home
- UTHR
as 09-18-2025 1:35pm EST
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 13.8B | IPO Year: | 1999 |
| Target Price: | $449.13 | AVG Volume (30 days): | 884.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 25.63 | EPS Growth: | 17.94 |
| 52 Week Low/High: | $266.98 - $436.95 | Next Earning Date: | 10-29-2025 |
| Revenue: | $3,077,800,000 | Revenue Growth: | 17.62% |
| Revenue Growth (this year): | 13.89% | Revenue Growth (next year): | 5.68% |
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Sep 16 '25 | Sell | $399.94 | 4,000 | $1,601,062.10 | 3,130 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Sep 15 '25 | Sell | $397.95 | 4,000 | $1,591,535.64 | 3,130 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Sep 15 '25 | Sell | $400.02 | 22,500 | $9,012,624.13 | 14,330 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Sep 12 '25 | Sell | $403.67 | 4,000 | $1,615,900.00 | 3,130 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Sep 11 '25 | Sell | $397.23 | 4,000 | $1,588,904.00 | 3,130 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Sep 10 '25 | Sell | $398.72 | 4,000 | $1,594,872.80 | 3,130 | |
| Thompson Tommy G | UTHR | Director | Sep 10 '25 | Sell | $403.36 | 4,560 | $1,839,321.60 | 8,480 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Sep 9 '25 | Sell | $398.86 | 8,000 | $3,188,374.29 | 3,130 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Sep 9 '25 | Sell | $396.97 | 11,375 | $4,520,573.53 | 14,330 | |
| MALCOLM JAN | UTHR | Director | Sep 9 '25 | Sell | $400.29 | 700 | $280,203.00 | 520 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Liquidia Corporation (LQDA): A Bull Case Theory
Business Wire
2 days ago
United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum
Business Wire
6 days ago
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress
MT Newswires
6 days ago
United Therapeutics Insider Sold Shares Worth $3,183,777, According to a Recent SEC Filing
Zacks
7 days ago
Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?
Investor's Business Daily
8 days ago
United Therapeutics Price Strength Rating Jumps; Stock Soared 33% Last Week
Simply Wall St.
9 days ago
Evaluating United Therapeutics After 30% Rally and New FDA Approval in 2025
Simply Wall St.
10 days ago
MannKind (MNKD): A Fresh Look at Valuation Following New United Therapeutics Deal Expansion
Compare UTHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.